Lanreotide acetate - CAS 127984-74-1
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Lanreotide  is a a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Check for active clinical trials or closed clinical trials using this agent.
Publictions citing BOC Sciences Products
  • >> More
1.Development of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactions.
Ijaz M1, Bonengel S1, Zupančič O1, Yaqoob M1, Hartl M2, Hussain S3, Huck CW3, Bernkop-Schnürch A1. Expert Opin Drug Deliv. 2016 Apr 7:1-7. [Epub ahead of print]
OBJECTIVES: To develop a self nano-emulsifying delivery system (SNEDS) for model peptide lanreotide providing a protective effect towards thiol-disulfide exchange reactions.
2.Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel.
Zafra GM1, Luque PS2. Case Rep Oncol. 2016 Jan 28;9(1):56-61. doi: 10.1159/000433577.
Peritoneal mucinous carcinomatosis is an aggressive subtype of pseudomyxoma peritonei, which often leads to inoperable bowel obstruction and, ultimately, death. Due to the poor prognosis, treatment is often symptomatic and aimed at alleviating the symptoms - pain, nausea, and vomiting - associated with gastrointestinal obstruction. Due to their antisecretory activity, somatostatin analogues are commonly prescribed in such cases. In the case presented here, a patient diagnosed with disseminated peritoneal mucinous carcinomatosis of appendiceal origin responded well to symptomatic treatment with lanreotide Autogel(®) at a dose of 120 mg/28 days. More importantly, radiological evidence of a reduction in peritoneal ascites, indicative of antiproliferative activity, was observed. These findings are important, particularly given the negative impact of this disease on both quality of life and survival. This case adds to the growing body of evidence supporting the antiproliferative and antisecretory activity of lanreotide Autogel.
3.Fluoxetine induced Hypoglycaemia in a patient with persistent form of Congenital Hyperinsulinism (CHI) on Lanreotide Therapy.
Giri D, Price V, Yung Z, Didi M, Senthil S. J Clin Res Pediatr Endocrinol. 2016 Apr 18. doi: 10.4274/jcrpe.2818. [Epub ahead of print]
Antidepressant drugs are reported to cause alterations in blood glucose homeostasis in adults with diabetes mellitus. We report a patient with persistent congenital hyperinsulinism (CHI) who developed recurrent hypoglycaemia following Fluoxetine therapy. A 15-year-old girl with persistent CHI was initially managed with diazoxide therapy. She developed troublesome hypertrichosis, which affected her quality of life adversely. Diazoxide was then slowly weaned and stopped with the introduction of Octreotide, to which she responded well. Subcutaneous Lanreotide (long acting somatostatin analogue) was subsequently commenced (30mg, once monthly) as injecting Octreotide multiple times a day was proving to be difficult for the patient. The continuous blood glucose monitoring on monthly Lanreotide injections revealed good glycaemic control. Six months later, she developed depression due to psychosocial problems at school. She was commenced on Fluoxetine by the psychiatry team.
4.Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P1, Valle JW2, Lombard-Bohas C3, Cuthbertson DJ4, Perros P5, Holubec L6, Delle Fave G7, Smith D8, Niccoli P9, Maisonobe P10, Atlan P10, Caplin ME11; SYMNET study group. Dig Liver Dis. 2016 May;48(5):552-8. doi: 10.1016/j.dld.2015.12.013. Epub 2016 Jan 15.
BACKGROUND: Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 127984-74-1 Lanreotide acetate

Quick Inquiry

Verification code

Featured Items